TY - JOUR T1 - Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study36521 JF - Clin.J.Am.Soc.Nephrol. Y1 - 2011 A1 - Broeders,N.E. A1 - Hombrouck,A. A1 - Lemy,A. A1 - Wissing,K.M. A1 - Racape,J. A1 - Gastaldello,K. A1 - Massart,A. A1 - Steven Van Gucht A1 - Weichselbaum,L. A1 - De Mul,A. A1 - Bernard Brochier A1 - Isabelle Thomas A1 - Abramowicz,D. KW - 0 KW - 2009 KW - a KW - administration & dosage KW - Adult KW - adverse effects KW - Aged KW - Agent KW - Agents KW - alpha-Tocopherol KW - Analysis of Variance KW - antibodies KW - Antibodies,Neutralizing KW - Antibodies,Viral KW - Antibody KW - Antigens KW - article KW - Belgium KW - blood KW - Brussels KW - Case-Control Studies KW - Chi-Square Distribution KW - Class KW - clinic KW - Cohort Studies KW - Cohort study KW - Combination KW - Confidence Intervals KW - Control KW - data KW - Design KW - disease KW - DRUG KW - Drug Combinations KW - electronic KW - Female KW - GM KW - Histocompatibility Antigens Class I KW - Histocompatibility Antigens Class II KW - hospital KW - Humans KW - i KW - im KW - Immunization KW - immunology KW - Immunosuppressive Agents KW - improve KW - Increase KW - INFLUENZA KW - Influenza A Virus,H1N1 Subtype KW - Influenza Vaccines KW - Influenza,Human KW - interval KW - IS KW - journal KW - Kidney KW - Kidney Failure,Chronic KW - Kidney Transplantation KW - Luminex KW - Male KW - measurement KW - measurements KW - middle aged KW - objectives KW - ODDS RATIO KW - p KW - pandemic KW - PARTICIPANTS KW - Patient KW - patients KW - Polysorbates KW - POPULATION KW - Populations KW - prevalence KW - prevention & control KW - proportion KW - Ratio KW - Ratios KW - recommendation KW - Recommendations KW - regression analysis KW - RENAL KW - Renal Dialysis KW - Research KW - Research Support KW - response KW - result KW - results KW - SB - IM KW - serum KW - Squalene KW - study KW - surgery KW - technology KW - Therapy KW - Time Factors KW - Treatment Outcome KW - Vaccination KW - vaccine KW - vaccines KW - virology AB - BACKGROUND AND OBJECTIVES: In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There are few data concerning the immunogenicity or the security of the adjuvanted-A/H1N1 vaccine in transplanted and hemodialyzed patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Sera from 21 controls, 53 hemodialyzed (HD) patients, and 111 renal transplant recipients (RT) were sampled before (T0) and 1 month after (T1) a single dose of Pandemrix(R) vaccine (GSK Biologicals, AS03-adjuvanted). We measured the neutralizing antibodies against A/H1N1/2009, the geometric mean (GM) titers, the GM titer ratios (T1/T0) with 95% confidence intervals, and the seroconversion rate (responders: >/=4-fold increase in titer). The HLA and MICA immunization was determined by Luminex technology. RESULTS: The GM titer ratio was 38 (19 to 78), 9 (5 to 16), and 5 (3 to 6) for controls, HD patients, and RT patients, respectively (P < 0.001). The proportion of responders was 90%, 57%, and 44%, respectively (P < 0.001). In RT patients, the prevalence of histocompatibility leukocyte antigen (HLA) class I, histocompatibility leukocyte antigen class II, and MHC class I-related chain A immunization, was, respectively, 15%, 14%, and 14% before and 14%, 14%, and 11% after vaccination (P = 1, 1, and 0.39). CONCLUSIONS: The influenza A/H1N1-adjuvanted vaccine is of limited efficacy but is safe in renal disease populations. The humoral response is lower in transplanted versus hemodialyzed patients. Further studies are needed to improve the efficacy of vaccination in those populations VL - 6 CP - 11 U1 - 38093 M3 - http://dx.doi.org/10.2215/CJN.04670511 ER -